3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Sarcoma
2
Other solid neoplasm
2
Gastrointestinal
2
NET
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Sarcoma
2
Mesothelioma, Malignant
2
Unresectable Locally Advanced or Metastatic Solid Tumors
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Neoplasm Metastasis
1
MSI-H Colorectal Cancer
1
Gastro-enteropancreatic neuroendocrine tumor
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Anus Neoplasms
1
Advanced Refractory Solid Tumors
1
Interventions
Cisplatin
57
Pemetrexed
46
pembrolizumab
18
Nivolumab
15
Carboplatin
15
Gemcitabine
14
Cyclophosphamide
13
Radiotherapy
10
Drug Therapy
9
atezolizumab
8
Platinum
7
Ipilimumab
7
Doxorubicin
7
durvalumab
6
1,2-diaminocyclohexaneplatinum II citrate
6
tremelimumab
5
sodium thiosulfate
5
Vinorelbine
5
Radiotherapy, Intensity-Modulated
5
Interleukin-2
5
Chemotherapy, Adjuvant
5
Cerebral Decortication
5
sargramostim
4
fludarabine
4
defactinib
4
aldesleukin
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
cediranib
3
Photochemotherapy
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
regorafenib
×
Other solid neoplasm
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled